For two years, “what will the FDA do?” was the biggest open question in peptides. In July 2026 we got a partial answer — and the headlines oversimplified it. Here is what actually happened.
What the committee voted
On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides and voted to recommend six of them — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for the 503A list of bulk substances licensed pharmacies may compound. It voted against the seventh, DSIP. BPC-157 passed narrowly, 8–6, and its recommendation was tied to a specific proposed use (ulcerative colitis) rather than general wellness.
The part the headlines skipped
The committee voted over the objection of the FDA’s own scientists, whose briefing documents concluded the evidence did not support adding any of the seven, citing short, underpowered studies. So this was the advisory panel disagreeing with FDA staff — not the agency itself approving anything.
Why it is not a green light
The vote is advisory and non-binding. Before anything changes, the FDA must run its own formal rulemaking — a proposed rule, a public comment period, then a final rule — and it can decline to follow the committee. The agency has already signaled it may not add BPC-157 despite the vote. As of today, none of these peptides is FDA-approved, and none can be lawfully compounded on the strength of this vote alone.
What to watch next
- Whether the FDA issues a proposed rule, and which peptides and uses it includes.
- The public comment period that would follow any proposal.
- A separate review of five more peptides (including GHK-Cu and Melanotan II) expected by early 2027.
We log each development as it is confirmed on the 2026 Updates page.
Bottom line
July 2026 moved the story forward, but it did not end it. The responsible read is “recommended, not approved” — and the right next step is still a licensed provider, not an online checkout.